Dbvt stock quote, history, news and other vital information to help you with your stock trading and investing. Successful initial public offering ipo for dbv technologies. Technology and life sciences ipo survey 2015, first half. Dbv technologies and aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist. Dbv technologies down 5% on pricing shares offering apr. Nasdaq gs stock quote dbv technologies sa bloomberg. Successful initial public offering ipo for dbv technologies on the. These institutions hold a total of 44,251,730 shares. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. In depth view into dbv technologies shares outstanding including historical data from 2014, charts, stats and industry comps. Dbv technologies sa is a biopharmaceutical company. Successful initial public offering ipo for dbv technologies download pdf 401 kb 2012. This prospectus is also available in electronic form to australian residents on costas offer website. Dbv technologies announces full exercise of underwriters option.
Dbvt today announced topline results from the pepites peanut epit efficacy and safety phase iii trial evaluating the safety and efficacy of viaskin peanut in children. Dbv technologies forms magic partnership with nestle. Dbv technologies will host a conference call today, october 20, 2017, at 5. Dbv technologies undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Dbvt today announced its cash and cash equivalents as of.
Dbv technologies announces fda acceptance of bla filing for viaskin peanut for the treatment of peanut allergy. Dbv technologies to attend upcoming investor conferences. Dbv technologies sa is a biotechnology company that provides therapy for food and pediatric allergy patients. Dbv technologies sa is a publicly owned french biopharmaceutical firm headquartered in bagneux, france. Dbv technologies reports september 30, 2017 cash position. Viaskin peanut receives fda fast track designation download pdf 18 kb 2012. Dbv technologies announces filing of 2019 universal registration. Dbv technologies provides update on regulatory progress. Dbv technologies investors go into shock with filing withdrawal. Monthly information regarding the total number of voting rights and total number of shares of th. Dbv technologies is a global biopharmaceutical company thats pioneering investigational epicutaneous immunotherapy epit to potentially treat millions of people suffering from life. Dbv technologies sa announces pricing of global offering torreya.
Largest shareholders include baker brothers advisors lp, boxer capital, llc, deerfield. Oct 20, 2017 dbv technologies announces topline results of phase iii clinical trial in peanutallergic patients four to 11 years of age. Persons who access the electronic version of this prospectus should ensure that they download and read the entire prospectus. En paris stock quote dbv technologies sa bloomberg. While its always nice to make more money than you expected, a company with predictable free cash flow is stable and good. Facebook twitter linkedin download from the app store. Dbv technologies announces topline results of phase iii.
Get breaking news and analysis on dbv technologies s. Dbv technologies announces results of its 2020 ordinary and extraordinary general meeting. Stock information investor faqs corporate governance. When available, copies of the final prospectus relating to. Dbv technologies is known for developing viaskin technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. About dbv technologies dbv technologies is developing viaskin, a proprietary technology platform with broad potential applications in immunotherapy. Dbv technologies would like the investors to pay attention to section 4 risk factors contained in the registration document and the update registered with the amf and section 2 risk factors relating to the offer. Free forex prices, toplists, indices and lots more. Please download the free adobe acrobat reader to view these documents. Dbvt dbv technologies stock price and discussion stocktwits. A company with wild swings in its free cash flow warrants further research. Dbvt stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on.
En paris including stock price, stock chart, company news, key statistics, fundamentals and company profile. The prospectus include essentially the same information as facebooks s1 filing to ipo, but with more polished. Dbv technologies is developing viaskin, an investigational proprietary technology platform with broad potential applications in. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. Dbv technologies reports march 31, 2020 cash position download pdf kb 2020. Dbv technologies announces the launch of a proposed global offering of ordinary shares, which may be in the form of american depositary shares, and reports september 30, 2019 cash position. When available, copies of the final prospectus relating to the offering may be obtained from. Netlink nbn trust, which owns 100% of the units in netlink trust, has a nationwide network that is the foundation of singapores next generation nationwide broadband network next gen nbn, over which ultrahighspeed internet access is delivered throughout mainland singapore and its connected islands. Nasdaq gs including stock price, stock chart, company news, key statistics, fundamentals and company profile. Successful initial public offering ipo for dbv technologies on the nyse euronext regulated market in paris dbv technologies raises 40. A dbv technologies announces results of its 2020 ordinary and extraordinary general meeting. Dbv technologies focuses on the development of innovative products for the diagnosis and treatment of food allergies. Oct 31, 2017 dbv technologies reports september 30, 2017 cash position.
Dbvt ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Dbv technologies announces closing of global offering and. Viaskin peanut clinical development has received fast track designation from the us. Dbvt, a clinicalstage biopharmaceutical company, today announced the settlement and delivery on. Dbv technologies provides update on regulatory progress for viaskin peanut. Dbvt stock, price quote and chart, trading and investing tools. Announces pricing of global offering bagneux, france october 22, 2014 dbv technologies euronext. This is the initial public offering of our american depositary shares, or adss. Dbvt dbv technologies sa summary, stock quote and news. Jun 07, 2016 dbv technologies forms magic partnership with nestle.
Announces proposed global offering bagneux, france october 20, 2014 dbv technologies euronext. They are a clinicalstage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called viaskin. Copies of the prospectus approved by the amf march 12, 2012 under the. Fr0010417345 the following is courtesy of corporate press release distributed by globe newswire bagneux, france, july 20, 2015 dbv technologies the company euronext. Why dbv technologies sa plummeted and aimmune therapeutics. The prospectus is also available on the websites of dbv technologies. A dbv technologies announces the launch of a proposed global offering of ordinary shares, which may be in the form of american depositary shares, and reports december 31, 2019. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these. Stock quotes euronext amsterdam realtime stock prices aex, amx, ascx. Dbv technologies to attend upcoming investor conferences twitter. Dbv technologies announces results of its 2020 ordinary and extraordinary general meeting download pdf 201 kb 2020. Dbvt has 96 institutional owners and shareholders that have filed dg or f forms with the securities exchange commission sec.
This preliminary prospectus supplement and the accompanying prospectus are not an. The company focuses on discovering, developing, manufacturing, and commercializing treatments for severe allergies in the united states and other global markets. Dbv technologies archives isin international securities. Dbv technologies decision to pull its viaskin peanut filing leaves the. Viaskin peanut clinical development has received fast track designation from the us food and drug administration. Biopharmaceutical food allergy treatments dbv technologies. May 03, 2012 the roadshow site also hosts the prospectus for investors embedded below. Dbv technologies dbvt says phase iii trial of viaskin peanut in patients four to 11 years of age did not reach primary endpoint article related press releases 1 related articles 1 stock. Edt after announcing that its peanut allergy treatment, viaskin peanut, failed albeit not by much a phase 3 trial.
Bagneux, france october 22, 2014 dbv technologies euronext. Fr0010417345, a clinicalstage specialty biopharmaceutical company announced today that it intends to offer and sell, subject to market and. Dbv technologies therapies are investigational and not fda approved. Fr0010417345, a clinicalstage specialty biopharmaceutical company announced today the pricing of its global offering of. Et on seeking alpha dbv technologies expands leadership team. The free cash flow jitter of a stock measures how much the companys free cash flow varies from its historical trend, on average. Dbvt 12 month eps 12 month eps the style scores are a complementary set of indicators to use alongside the zacks rank. Dbv technologies reports full year 2015 financial results. Dbv technologies dbvt says phase iii trial of viaskin. Its lead product candidate is viaskin peanut, an immunotherapy product, which has completed phase iii clinical trial for the treatment of peanut allergies in children, adolescents, and adults. Dbv technologies announces filing of 2019 universal registration document and 2019 annual report on form 20f mar.
326 155 1367 606 15 977 739 328 493 258 628 506 1242 130 15 1407 449 1437 1031 785 1364 1401 1028 462 1033 1458 125 248 1424 1308 484